Innocoll Revenue and Competitors
Estimated Revenue & Valuation
- Innocoll's estimated annual revenue is currently $10.5M per year.
- Innocoll's estimated revenue per employee is $201,000
Employee Data
- Innocoll has 52 Employees.
- Innocoll grew their employee count by -57% last year.
Innocoll's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Executive Director Business Development | Reveal Email/Phone |
3 | Executive Director, Sales & Marketing | Reveal Email/Phone |
4 | Head US Technical Services | Reveal Email/Phone |
5 | Head Research and Development | Reveal Email/Phone |
6 | VP Technical Operations Innocoll | Reveal Email/Phone |
7 | Director Finance | Reveal Email/Phone |
8 | Executive Director - Head Quality | Reveal Email/Phone |
9 | Director Finance | Reveal Email/Phone |
10 | Chief Financial Officer | Reveal Email/Phone |
Innocoll Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $43.2M | 215 | 6% | N/A | N/A |
#2 | $81.8M | 407 | 10% | N/A | N/A |
#3 | $11.7M | 58 | 0% | N/A | N/A |
#4 | $1011.8M | 5034 | -9% | N/A | N/A |
#5 | $44.8M | 223 | 1% | N/A | N/A |
#6 | $13.1M | 65 | 5% | N/A | N/A |
#7 | $16.5M | 82 | 41% | N/A | N/A |
#8 | $17.3M | 86 | -5% | N/A | N/A |
#9 | $67.9M | 338 | 23% | N/A | N/A |
#10 | $14.9M | 74 | 7% | N/A | N/A |
What Is Innocoll?
Innocoll is a specialty pharmaceutical company focused on the development and commercialization of pharmaceutical technologies to meet some of today's most important healthcare challenges. We utilize our proprietary collagen-based technology platform to develop biodegradable and fully resorbable products. Our processes and technologies enable us to control the drug elution dynamics, texture, consistency, resorption time and other physical characteristics of the finished product. All of our native collagen products are manufactured at our certified, state-of-the-art, fully integrated plant in Saal, Germany. Our current late-stage product pipeline is focused on addressing patient needs for postsurgical pain management. Our lead product, XARACOLL® (bupivacaine HCl) Implant, was approved by the U.S. Food and Drug Administration in August 2020
keywords:N/A
N/A
Total Funding
52
Number of Employees
$10.5M
Revenue (est)
-57%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Innocoll News
NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd. in the U.S. and a trademark of DURECT Corporation outside of the U.S. SABER®...
... Integra LifeSciences Holdings Corporation, Innocoll Holdings, FzioMed, Atrium Medical Corporation, MAST Biosurgery, Anika Therapeutics.
... Announces Proposed Securities Class Action Settlement on Behalf of Purchasers of Innocoll publicly traded securities. April 04, 2022 09:00 ET | Source:...
Other Companies in Pennsylvania
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.2M | 55 | 6% | N/A |
#2 | N/A | 77 | 28% | N/A |
#3 | $23.2M | 86 | 87% | N/A |